{"id":"https://openalex.org/W2272726499","doi":null,"title":"Identification and management of toxicities from immune checkpoint-blocking drugs.","display_name":"Identification and management of toxicities from immune checkpoint-blocking drugs.","publication_year":2014,"publication_date":"2014-11-01","ids":{"openalex":"https://openalex.org/W2272726499","mag":"2272726499","pmid":"https://pubmed.ncbi.nlm.nih.gov/25384885"},"language":"en","primary_location":{"id":"pmid:25384885","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25384885","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089117793","display_name":"Benjamin A. Teply","orcid":"https://orcid.org/0000-0002-7366-6212","observed_orcids":["https://orcid.org/0000-0002-7366-6212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin A Teply","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5014494747","display_name":"Evan J. Lipson","orcid":"https://orcid.org/0000-0003-2976-0911","observed_orcids":["https://orcid.org/0000-0003-2976-0911"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evan J Lipson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.5697,"has_fulltext":false,"cited_by_count":57,"citation_normalized_percentile":{"value":0.9740072,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"28 Suppl 3","issue":null,"first_page":"30","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9869999885559082},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8600000143051147},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/toxicity-mechanisms","display_name":"toxicity mechanisms","score":0.6740000247955322},{"id":"https://openalex.org/keywords/patient-assessment","display_name":"patient assessment","score":0.4659999907016754},{"id":"https://openalex.org/keywords/risk-reduction","display_name":"risk mitigation","score":0.6819999814033508},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.6610000133514404},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.875},{"id":"https://openalex.org/keywords/multidisciplinary-care","display_name":"multidisciplinary care","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8678337931632996},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8618911504745483},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7910539507865906},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7827566862106323},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5553377270698547},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.46521639823913574},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46140021085739136},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4434196650981903},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.43621134757995605},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.41582775115966797},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3646036982536316},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2854878902435303},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23260435461997986},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D004760","descriptor_name":"Enterocolitis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004760","descriptor_name":"Enterocolitis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D004760","descriptor_name":"Enterocolitis","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056486","descriptor_name":"Chemical and Drug Induced Liver Injury","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D056486","descriptor_name":"Chemical and Drug Induced Liver Injury","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:25384885","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25384885","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:2272726499","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25384885","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W173616099","https://openalex.org/W1766682057","https://openalex.org/W1907829837","https://openalex.org/W1965494873","https://openalex.org/W1969965329","https://openalex.org/W1971608284","https://openalex.org/W1976743909","https://openalex.org/W1979811833","https://openalex.org/W1979895328","https://openalex.org/W1982300885","https://openalex.org/W1987234856","https://openalex.org/W1990675339","https://openalex.org/W2022430110","https://openalex.org/W2029073555","https://openalex.org/W2040190056","https://openalex.org/W2066671159","https://openalex.org/W2068946981","https://openalex.org/W2080878900","https://openalex.org/W2081521066","https://openalex.org/W2096060394","https://openalex.org/W2096511276","https://openalex.org/W2097560051","https://openalex.org/W2097995306","https://openalex.org/W2098414192","https://openalex.org/W2101653483","https://openalex.org/W2107150019","https://openalex.org/W2107484016","https://openalex.org/W2109465910","https://openalex.org/W2109653150","https://openalex.org/W2116548718","https://openalex.org/W2116813877","https://openalex.org/W2118982164","https://openalex.org/W2119198740","https://openalex.org/W2126453999","https://openalex.org/W2135885240","https://openalex.org/W2137349687","https://openalex.org/W2139591061","https://openalex.org/W2143163879","https://openalex.org/W2148576689","https://openalex.org/W2158792250","https://openalex.org/W2160834915","https://openalex.org/W2164918836","https://openalex.org/W2171190137","https://openalex.org/W2202787350","https://openalex.org/W2205394433","https://openalex.org/W2325469667","https://openalex.org/W2598288537"],"related_works":["https://openalex.org/W2125082756","https://openalex.org/W1605630196","https://openalex.org/W2736008571","https://openalex.org/W2521107699","https://openalex.org/W2259730793","https://openalex.org/W2325090117","https://openalex.org/W2481870775","https://openalex.org/W3029766637","https://openalex.org/W3000961096","https://openalex.org/W2136314765"],"abstract_inverted_index":{"Immune":[0],"checkpoint-blocking":[1,70],"drugs":[2],"such":[3],"as":[4,13],"ipilimumab,":[5],"pembrolizumab,":[6],"and":[7,52,77,82,118],"nivolumab":[8],"have":[9],"demonstrated":[10],"clinical":[11],"efficacy":[12],"anticancer":[14],"agents.":[15],"Through":[16],"modulation":[17],"of":[18,32,44,65,89],"immunoregulatory":[19],"molecules,":[20],"these":[21,36],"novel":[22],"therapeutics":[23],"can":[24],"produce":[25],"durable":[26],"cancer":[27],"remissions":[28],"in":[29,74],"a":[30,99,106],"variety":[31],"tumor":[33],"types.":[34],"As":[35],"medications":[37],"are":[38],"administered":[39],"to":[40,50,104,109],"an":[41],"increasing":[42],"number":[43],"patients,":[45],"clinicians":[46],"must":[47,96],"be":[48,97],"able":[49],"recognize":[51],"treat":[53],"the":[54,62,87],"associated":[55,67],"immune-related":[56],"side":[57],"effects.":[58],"This":[59],"review":[60],"summarizes":[61],"unique":[63],"mechanisms":[64],"toxicity":[66],"with":[68],"immune":[69,93],"drugs,":[71],"appropriate":[72],"steps":[73],"patient":[75,84,91],"evaluation,":[76],"strategies":[78],"for":[79],"mitigating":[80],"risk":[81],"optimizing":[83],"outcomes.":[85],"Although":[86],"management":[88],"each":[90],"receiving":[92],"checkpoint-blockade":[94],"therapy":[95],"individualized,":[98],"conceptual":[100],"framework":[101],"upon":[102],"which":[103],"base":[105],"multidisciplinary":[107],"approach":[108],"best":[110],"practices":[111],"will":[112],"help":[113],"oncology":[114],"practitioners":[115],"deliver":[116],"safe":[117],"effective":[119],"care.":[120]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":18},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}